incretin glp 1 The Impact: a new era in metabolic disease and obesity drug development Incretin hormones and obesity -
Description
Combination Therapy: DPP-4 inhibitors may be used as monotherapy in individuals with mild to moderate diabetes who are non-compliant or intolerant of metformin and other first-line agents
The results of clinical trials have not matched expectations based on the positive results from preclinical studies
The DPP-4 inhibitor linagliptin restores -cell function and survival in human isolated islets through GLP-1 stabilization
Send us a message our pharmacists can help with the basics and next steps
Dont forget about daily movement
